AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Hyaluronan-binding protein 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q14520

UPID:

HABP2_HUMAN

Alternative names:

Factor VII-activating protease; Factor seven-activating protease; Hepatocyte growth factor activator-like protein; Plasma hyaluronan-binding protein

Alternative UPACC:

Q14520; A8K467; B7Z8U5; F5H5M6; O00663

Background:

Hyaluronan-binding protein 2, also known as Factor VII-activating protease, plays a crucial role in the coagulation cascade by activating Factor VII and converting pro-urokinase into its active form. It is unique in its ability to cleave the alpha-chain of fibrinogen without initiating fibrin clot formation or fibrinolysis directly. This protein's multifaceted role extends to cell proliferation and migration, suggesting a potential tumor suppressor function.

Therapeutic significance:

Given its association with non-medullary thyroid cancer and its pivotal role in cell proliferation and migration, Hyaluronan-binding protein 2 presents a promising target for therapeutic intervention. Understanding the role of Hyaluronan-binding protein 2 could open doors to potential therapeutic strategies, particularly in the context of thyroid cancer treatment and possibly other malignancies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.